Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 15 studies | 31% ± 16% | |
peripheral blood | 10 studies | 26% ± 9% | |
intestine | 8 studies | 30% ± 11% | |
kidney | 7 studies | 30% ± 11% | |
lymph node | 4 studies | 28% ± 19% | |
brain | 4 studies | 28% ± 7% | |
liver | 4 studies | 26% ± 9% | |
pancreas | 3 studies | 43% ± 8% | |
bone marrow | 3 studies | 17% ± 1% | |
uterus | 3 studies | 28% ± 16% | |
breast | 3 studies | 20% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 8741.91 | 226 / 226 | 100% | 171.91 | 406 / 406 |
ovary | 100% | 3818.08 | 180 / 180 | 100% | 94.97 | 430 / 430 |
pancreas | 100% | 5171.64 | 328 / 328 | 100% | 115.98 | 178 / 178 |
skin | 100% | 3963.43 | 1809 / 1809 | 100% | 108.24 | 472 / 472 |
thymus | 100% | 5338.96 | 653 / 653 | 100% | 151.95 | 605 / 605 |
uterus | 100% | 4091.22 | 170 / 170 | 100% | 166.15 | 459 / 459 |
esophagus | 100% | 4721.72 | 1444 / 1445 | 100% | 79.41 | 183 / 183 |
lung | 100% | 4821.05 | 578 / 578 | 100% | 131.08 | 1154 / 1155 |
prostate | 100% | 4991.64 | 245 / 245 | 100% | 194.99 | 501 / 502 |
breast | 100% | 4193.34 | 459 / 459 | 100% | 142.56 | 1115 / 1118 |
stomach | 100% | 5076.65 | 359 / 359 | 100% | 120.16 | 285 / 286 |
intestine | 100% | 4816.78 | 966 / 966 | 100% | 141.34 | 525 / 527 |
bladder | 100% | 3701.90 | 21 / 21 | 100% | 148.69 | 502 / 504 |
kidney | 100% | 10007.31 | 89 / 89 | 99% | 144.36 | 888 / 901 |
brain | 98% | 2178.28 | 2589 / 2642 | 100% | 88.44 | 705 / 705 |
adrenal gland | 100% | 4273.10 | 258 / 258 | 97% | 62.05 | 222 / 230 |
adipose | 100% | 3985.53 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 226.56 | 29 / 29 |
spleen | 100% | 5821.61 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 164.82 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 99.04 | 1 / 1 |
blood vessel | 100% | 3573.40 | 1329 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 94.38 | 79 / 80 |
heart | 95% | 2201.45 | 820 / 861 | 0% | 0 | 0 / 0 |
muscle | 94% | 1612.13 | 752 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 91% | 3131.94 | 843 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0044597 | Biological process | daunorubicin metabolic process |
GO_0044598 | Biological process | doxorubicin metabolic process |
GO_0019853 | Biological process | L-ascorbic acid biosynthetic process |
GO_0019640 | Biological process | glucuronate catabolic process to xylulose 5-phosphate |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0046185 | Biological process | aldehyde catabolic process |
GO_0110095 | Biological process | cellular detoxification of aldehyde |
GO_1901687 | Biological process | glutathione derivative biosynthetic process |
GO_0006629 | Biological process | lipid metabolic process |
GO_0042840 | Biological process | D-glucuronate catabolic process |
GO_0016324 | Cellular component | apical plasma membrane |
GO_0005615 | Cellular component | extracellular space |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005829 | Cellular component | cytosol |
GO_0045202 | Cellular component | synapse |
GO_0047655 | Molecular function | allyl-alcohol dehydrogenase activity |
GO_0004032 | Molecular function | aldose reductase (NADPH) activity |
GO_0160163 | Molecular function | S-nitrosoglutathione reductase (NADPH) activity |
GO_1990002 | Molecular function | methylglyoxal reductase (NADPH) (acetol producing) activity |
GO_0004033 | Molecular function | aldo-keto reductase (NADPH) activity |
GO_0080007 | Molecular function | S-nitrosoglutathione reductase (NADH) activity |
GO_0047941 | Molecular function | glucuronolactone reductase activity |
GO_0047939 | Molecular function | L-glucuronate reductase activity |
GO_0047956 | Molecular function | glycerol dehydrogenase (NADP+) activity |
GO_0004745 | Molecular function | all-trans-retinol dehydrogenase (NAD+) activity |
GO_0005515 | Molecular function | protein binding |
Gene name | AKR1A1 |
Protein name | Aldo-keto reductase family 1 member A1 (EC 1.1.1.2) (EC 1.1.1.372) (EC 1.1.1.54) (Alcohol dehydrogenase [NADP(+)]) (Aldehyde reductase) (Glucuronate reductase) (EC 1.1.1.19) (Glucuronolactone reductase) (EC 1.1.1.20) Aldo-keto reductase family 1 member A1 |
Synonyms | ALR ALDR1 |
Description | FUNCTION: Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols. Displays enzymatic activity towards endogenous metabolites such as aromatic and aliphatic aldehydes, ketones, monosaccharides and bile acids, with a preference for negatively charged substrates, such as glucuronate and succinic semialdehyde . Functions as a detoxifiying enzyme by reducing a range of toxic aldehydes. Reduces methylglyoxal and 3-deoxyglucosone, which are present at elevated levels under hyperglycemic conditions and are cytotoxic. Involved also in the detoxification of lipid-derived aldehydes like acrolein (By similarity). Plays a role in the activation of procarcinogens, such as polycyclic aromatic hydrocarbon trans-dihydrodiols, and in the metabolism of various xenobiotics and drugs, including the anthracyclines doxorubicin (DOX) and daunorubicin (DAUN) . Displays no reductase activity towards retinoids (By similarity). . |
Accessions | ENST00000351829.9 ENST00000471651.1 ENST00000372070.7 P14550 Q5T621 V9GYG2 ENST00000481885.5 ENST00000621846.4 V9GYP9 ENST00000434299.5 |